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Abstract
Background: The toxicity of amyloid-β (Aβ) peptide present in the brain of Alzheimer’s disease (AD) patients is
thought to be mediated via the increased secretion of pro-inflammatory mediators, which can lead to neuronal
dysfunction and cell death. In addition, we have previously shown that inflammation can affect Aβ generation.
More recently, we have reported that in vitro administration of the anti-inflammatory mediator Annexin A1 (ANXA1)
following an inflammatory challenge suppressed microglial activation and this effect was mediated through formyl
peptide receptor-like 1 (FPRL1/FPR2) signalling. The aim of this study was to determine the potential role of ANXA1
in the generation and clearance of Aβ.
Methods: We first compared ANXA1 protein expression in the brains of AD patients and healthy controls as well as
in the 5XFAD model of AD. To determine the role of ANXA1 in the processing of amyloid precursor protein (APP)
and the degradation of Aβ, N2a neuroblastoma cells were treated with human recombinant ANXA1 or transfected
with ANXA1 siRNA. We also investigated the effect of ANXA1 on Aβ phagocytosis and microglial activation in BV2
cells treated with synthetic Aβ.
Results: Our data show that ANXA1 is increased in the brains of AD patients and animal models of AD at early
stages. ANXA1 was able to reduce the levels of Aβ by increasing its enzymatic degradation by neprilysin in N2a
cells and to stimulate Aβ phagocytosis by microglia. These effects were mediated through FPRL1 receptors. In
addition, ANXA1 inhibited the Aβ-stimulated secretion of inflammatory mediators by microglia.
Conclusions: These data suggest that ANXA1 plays a pivotal role in Aβ clearance and supports the use of ANXA1
as potential pharmacological tool for AD therapeutics.
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Background
Amyloid-β (Aβ) peptide is present in high levels in the
brains of Alzheimer’s disease (AD) patients and is closely
associated with the pathogenesis of the disease. Aβ pep-
tides are toxic products derived from the catalytic cleavage
of a larger amyloid precursor protein (APP) by β- and γ-
secretases [1]. The toxicity of Aβ is thought to be medi-
ated via the secretion of neurotoxic inflammatory media-
tors and reactive oxygen species (ROS) from glial cells [2].
There is convincing evidence that Aβ is able to prime
microglia [3], inciting an inflammatory response and the
release of neurotoxic cytokines, ROS, complement factors
and nitric oxide (NO), which can all contribute to neur-
onal dysfunction and cell death [4]. Importantly, we previ-
ously found a direct link between pro-inflammatory
cytokines and Aβ generation by showing that certain cyto-
kines such as tumour necrosis factor (TNF)α and inter-
feron (IFN)γ can transcriptionally upregulate β-secretase
beta-site APP cleaving enzyme 1 (BACE1) [5, 6]; this has
also been confirmed in animal models of inflammation
[7]. Therefore, a combination of dying neurones and Aβ
accumulated via active synthesis would further stimulate
microglia, creating a self-perpetuating cycle. It has to be
noted that the activation of microglia may not only con-
tribute to disease progression but could also have beneficial
effects. Activated microglia can reduce Aβ accumulation
by increasing its phagocytosis, clearance and degradation
[8, 9] and the release of anti-inflammatory molecules in-
cluding certain cytokines, growth factors and the resolving
molecule Annexin A1 (ANXA1).
ANXA1 is a glucocorticoid anti-inflammatory medi-
ator in the peripheral system [10, 11], which plays a
key role in ensuring the effective and selective removal
of apoptotic neuron-like cells under inflammatory and
non-inflammatory conditions [12]. In the brain, ANXA1
is abundant in microglial cells and in the endothelium of
the blood brain barrier (BBB), where it plays an important
role in maintaining BBB tightness [13, 14]. Microglia
have the capacity to synthesise and release ANXA1 [15],
and ANXA1 function is associated with anti-inflammatory
actions, regulating leukocyte extravasation [16–18], macro-
phage phagocytosis [19] and glucocorticoid action [20–22].
During pathological states, it has been proposed that
ANXA1 has a protective role by limiting inflammatory
damage [23]. This was further supported by our observa-
tions whereby incubation of microglia with recombinant
ANXA1 resulted in reduced microglial activation following
lipopolysaccharide (LPS) stimulation [12]. Our studies have
also shown that ANXA1 is upregulated in human micro-
glia surrounding Aβ plaques, supporting a possible role for
the protein in regulating the microglial response to amyl-
oid plaques [12, 15]. The identification of formyl peptide
receptor-like 1 (FPRL1/FPR2) as a receptor for ANXA1
suggests an intriguing link between Aβ and FPRL1 [24].
The binding of ANXA1 to FPRL1 has been associated with
the modulation of microglial phagocytosis [12, 25] and
pro-inflammatory release [26], while it was suggested that
the interaction of different aggregated/fibrillar forms of Aβ
with microglia changes the expression pattern of FPRL1,
affecting the phagocytic function of microglia [27].
We therefore hypothesized that ANXA1 has a protect-
ive role in resolving neuroinflammation in the AD brain,
by affecting Aβ generation and/or degradation and
modulating microglial functions such as phagocytosis
and the secretion of cytokines and neurotoxic species,
which could cause neuronal damage. The aim of this
study was to define the role of ANXA1 in APP process-
ing and Aβ degradation in vitro and to evaluate whether
ANXA1 is able to affect Aβ-induced changes in micro-
glia function.
Methods
Reagents and antibodies
Antibodies used included 6E10 against Aβ1-16 (Covance),
4G8 against Aβ17-24 (Covance), anti-BACE1 antibody
(Cell Signalling), anti-neprilysin antibody (Santa Cruz),
anti-insulin degrading enzyme (IDE) antibody (Abcam),
anti-ANXA1 antibody (Zymed), anti-β-actin antibody
(Abcam), anti-IgG antibody (Abcam), anti-FPRL1/FPR2
antibody (Acris Antibodies GmbH) and anti-IgG FITC
conjugated antibody (AbD Serotec). Full-length human re-
combinant (hr) ANXA1 was obtained as previously de-
scribed [16], and protein was purified by GTP Technology
(Labege Cedex). Synthetic Aβ1–42, 5-FAM-labelled Aβ1–42
and Aβ1–42 scrambled peptides were obtained from Ana-
spec. Synthetic Aβ1–42 was prepared by suspension of the
lyophilised Aβ1–42 in DMSO to 500 μM and then diluted
to different concentrations ranging from 0.1 to 3 μM with
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cold DMEM. FPR2 inhibitors WRW4 and Boc-1 were ob-
tained from Tocris Bioscience. Tissue culture reagents
were obtained from Invitrogen. All other chemicals and
reagents were purchased from Sigma-Aldrich, Qiagen and
Invitrogen.
Human postmortem brain samples
Human brains were obtained from routine autopsies at
the London Neurodegenerative Diseases Brain Bank at
King’s College London and the Swedish Brain Bank in
accordance with laws and the permission of the ethical
committees. The control group included brains from
subjects who died either of non-neurological diseases or
traffic accidents and had no history of long-term illness
or dementia. Frontal cortex was compared of control
brains (n = 20, 12 males, 8 females, range 40–97 years,
mean age 73.24 ± 4 years) and sporadic AD cases (n = 22,
11 males, 11 females, range 42–98 years, mean age
79.09 ± 3 years).
Immunohistochemistry
For immunohistochemistry, sections were deparaffinised
in xylene and rehydrated in decreasing alcohols. En-
dogenous peroxidase was inhibited by incubation in
0.3 % v/v H2O2 in 0.1 M phosphate buffered saline (PBS)
for 30 min at room temperature. Sections were rinsed
twice in 0.05 M Tris-buffered saline (TBS) and incu-
bated for 1 h at room temperature with 10 % BSA
(Sigma-Aldrich) containing 0.05 % v/v Triton X-100 to
saturate nonspecific binding; sections were then incu-
bated for 16 h at 4 °C with ANXA1 antibody (1:1000),
rinsed twice in TBS-containing 0.05 % v/v Triton X-100,
incubated in biotinylated goat-anti-rabbit secondary
antibody (Vector Laboratories) at the dilution of 1:100
for 2 h at room temperature, rinsed twice with TBS and
incubated for 45 min in the avidin-biotin complex
(ABC) conjugated with horseradish peroxidase (HRP) in
TBS (Vector Laboratories). Following two washes in
TBS, the reactions were developed in 0.025 % diamino-
benzidine and 0.01 % H2O2 (Sigma-Aldrich) in TBS for
5 min. Sections were rinsed twice in TBS, dehydrated
and mounted under DPX mountant (VWR Inter-
national) for bright-field microscopic analysis.
Animals
All animals were kept in individually ventilated cages
with controlled temperature and humidity, food and
water ad libitum and a 12:12-h light-dark cycle. Twelve-
and 26-month-old male 5XFAD transgenic mice and
their wild-type littermates (n = 6 per group) were used
and were obtained from the Jackson Laboratory. These
mice overexpress both mutant human APP(695) with
the Swedish (K670N, M671L), Florida (I716V) and
London (V717I) Familial Alzheimer’s Disease (FAD)
mutations and human PS1 harbouring two FAD muta-
tions, M146L and L286V. Expression of both transgenes
is regulated by neural-specific elements of the mouse
Thy1 promoter to drive overexpression in the brain.
5XFAD mice generate almost exclusively Aβ42 and rap-
idly accumulate massive cerebral levels [28]. Animals
were anaesthetised and transcardially perfused with ice-
cold 0.9 % saline. Brains were dissected and snap frozen
and were stored at −80 °C until used. All animal proce-
dures were approved by the UK Home Office and were
in accordance with the Animals (Scientific Procedures)
Act of 1986.
Cell lines and maintenance
The murine neuroblastoma cell line stably transfected
with the APP “Swedish” mutation (K595N/M596L),
hereafter referred to as N2asw, was a kind gift of G. Thi-
nakaran (University of Chicago). Cells were maintained
in a selective and undifferentiated state using 0.2 mg/ml
of the antibiotic G-418 in DMEM and Opti-MEM
(Gibco/Life Technologies), supplemented with 5 % foetal
bovine serum (FBS) and 50 U/ml penicillin, and 50 mg/
ml streptomycin sulphate. The human neuroblastoma
cell line SK-N-SH was cultured in DMEM supplemented
with 10 % FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin sulphate. The murine microglial cell line
BV2 was cultured in Roswell Park Memorial Institute
(RPMI) medium containing 5 % FBS, gentamycin
(50 mg/ml) and 1 % non-essential amino acids (NEAA).
Cells were grown in a 5 % CO2 incubator at 37 °C.
Treatments, transfection and infection
Cells were incubated with different concentrations of
human recombinant ANXA1 (hrANXA1), ranging from
0.04 to 5 μg/ml for 2–48 h in serum-free medium. In
some experiments, hrANXA1 treatment was combined
with 0.1–3 μM synthetic Aβ42 (Anaspec), non-selective
FPR inhibitor Boc1 (5 μg/ml) or FPR2 inhibitor WRW4
(0.5–5 μM), with hrANXA1 added 30 min before Aβ
and Boc1 or WRW4 added 20 min before hrANXA1.
For fluorescence-activated cell sorting (FACS) experi-
ments, BV2 cells were left in medium (containing FBS)
which they had conditioned overnight for 18 h, or this
was changed to fresh medium (containing FBS), prior to
addition of 5-FAM-labelled-Aβ42 or Aβ42 scrambled
(3 μg/ml) and anti-ANXA1-antibody (20 ng/ml) or anti-
IgG-antibody (20 ng/ml) for 3 h. For Image Stream ex-
periments, cells were incubated with 5-FAM-labelled-
Aβ42 or Aβ42 scrambled (5 μg/ml), with 5 μg/ml
hrANXA1 added 30 min before Aβ and 5 μM WRW4
added 20 min before hrANXA1.
N2asw cells were transfected with control or ANXA1
small interfering RNA (siRNA) (Gene Pharma) using
Lipofectamine® 2000 transfection reagent (Thermo Fischer
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Scientific) according to the manufacturer’s instructions
and harvested after 48 h.
BV2 cells were plated in six-well plates (300,000 cells/
well). After 48 h, when having reached 70–80 % of con-
fluence, cells were incubated for 18 h overnight at 37 °C
with medium containing lentivirus small hairpin RNA
(shRNA) murine ANXA1 with designated specific clones
named TRCN0000109725(A) and TRCN0000109728 (B)
as previously described [29]. Mock-infected cells (PKCO)
were used as control of infection procedure. Transduc-
tion efficiency and ANXA1 knockdown were verified by
Western blot analysis (Additional file 1: Figure S1).
Analysis of Aβ and sAPPα
Soluble APPα (sAPPα) and Aβ secreted in the condi-
tioned medium of N2asw cells were analysed by Western
blot. The volume of medium used was adjusted to pro-
tein concentrations measured in total cell lysates. An ali-
quot of the media was either run straight away on
NuPage 4–12 % Tris-glycine gel (Invitrogen) or Aβ was
pulled down overnight at 4 °C using Sepharose Protein
A (Zymed) and 4G8 (Covance). Samples were then
loaded in NuPage 4–12 % Tris-glycine gels and trans-
ferred onto nitrocellulose membranes. The membrane
was boiled in PBS for 5 min, blocked with non-fat milk
and incubated with 6E10 antibody at 1/1000 (a mono-
clonal antibody recognising amino acids 1–17 of human
Aβ (Covance)). Membranes were incubated with HRP
conjugated secondary in 5 % non-fat dried milk in Tris-
buffered saline with Tween (TBST) and developed using
ECL™ (GE Amersham) and Hyperfilm ECL™ (GE Amer-
sham) in an automated developer from Konica, SRX
101A.
Western blotting analysis
Cell lysates and brain homogenates were extracted with
RIPA (1 % Triton X-100, 1 % sodium deoxycholate,
0.1 % SDS, 150 mM NaCl, and 50 mM Tris-HCl, pH
7.2) supplemented with cOmplete™ protease inhibitor
cocktail (Roche), and equal amounts of protein samples
(20–80 μg) were separated in SDS-PAGE gels, followed
by immunoblotting with primary antibodies and de-
tected with HRP conjugated secondary in 5 % non-fat
dried milk or 5 % bovine serum albumin (BSA) in TBST.
Membranes were developed using ECL™ (GE Amersham)
reagents and using Hyperfilm ECL™ in an automated de-
veloper from Konica, SRX 101A. To re-probe blots for a
different protein, membranes were stripped with ReBlot
Plus Strong Antibody Stripping Solution (Millipore).
Digital images were quantified by densitometry using
ImageJ and adjusted for protein loading by normalising
to β-actin, GAPDH or tubulin, or full-length APP for
APP cleavage products.
β-secretase activity assay
β-secretase enzyme activity was measured in N2asw cell
lysates using a fluorimetric reaction (Abcam) according
to the manufacturer’s instructions.
Neprilysin activity assay
Treated cells were collected and resuspended in 10 mM
Tris-HCl pH 7.5 and incubated with 100 mM substrate
N-succinyl alanin-alanin-phenylalanin-7-amino-4-methyl-
coumarin (Sigma) for 30 min at 37 °C. Fluorescence was
measured at 390-nm excitation and 420-nm emission
wavelength, and results were adjusted to protein concen-
tration [30].
qPCR
Messenger RNA (mRNA) was extracted from treated
cells using the Direct-zol RNA Mini Prep system (Zymo
Research) according to the manufacturer’s instructions.
mRNAs were subjected to reverse-transcription quanti-
tative PCR (RT-qPCR) analysis using a two-step method
with an initial RT and subsequent real-time cycling as
reported previously [30] on a Stratagene Mx3000p block
cycler. GAPDH/Gapdh was used as an internal control
for mRNA. Primers used are listed in Table 1.
Fluorescence-activated cell sorting
BV2 microglial cells were plated in a 12-well plate over-
night in RPMI containing 5 % FBS. The following day,
the medium was either replaced with RPMI containing
1 % FBS or unchanged, and the cells were then incu-
bated with 3 μg/ml of 5-FAM-labelled Aβ1–42 or 5-
FAM-labelled scrambled-Aβ1–42, for 3 h. Following this,
the medium was removed and the cells were washed
with cold PBS and fixed with 2 % paraformaldehyde
(PFA) for 10 min. After this, cells were washed and col-
lected for analysis by FACS using FACSCalibur (Becton,
Table 1 List of primers used
Gene Forward Reverse
Arg1 CAGCACTGAGGAAAGCTGGT CAGACCGTGGGTTCTTCACA
BACE1 GGCGGGAGTGGTATTATGAGGTGA TATTGCTGCGGAAGGATGGTGA
FPR rs1 CCTTGGACCGCTGTATTTGT GTGCACATCCCCTCTAGCAT
Gapdh ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA
Il10 TAACTGCACCCACTTCCCAG AGGCTTGGCAACCCAAGTAA
Il4 GGTCTCAACCCCCAGCTAGT GCCGATGATCTCTCTCAAGTGAT
Il6 ATGGATGCTACCAAACTGGAT TGAAGGACTCTGGCTTTGTCT
MARCO ACAGAGCCGATTTTGACCAAG CAGCAGTGCAGTACCTGCC
MME GGTCCGCAGCTAAGGTCCAG GAGCTGGTCTCGGGAATGAC
RAGE CTTGCTCTATGGGGAGCTGTA GGAGGATTTGAGCCACGCT
Tgfb1 GGATACCAACTATTGCTTCAGCTCC AGGCTCCAAATATAGGGGCAGGGTC
Tnf AGGGATGAGAAGTTCCCAAATG CACTTGGTGGTTTGCTACGAC
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Dickinson and Company) with a 100-mW, 488-nm, air-
cooled argon laser. Data was measured from the FL1
channel (mean intensity of fluorescence in log scale)
with at least 10,000 events counted and analysed using
FlowJo software.
Image stream
BV2 cells (wild type, shRNA PKCO and shRNA ANXA1
492) were plated in sixwell plates. After 24 h, cells were in-
cubated for 3 h at 37 °C with 5 μg/ml of 5-FAM-labelled
Aβ1–42 added to BV2-conditioned medium. In order to in-
vestigate the effect of ANXA1 on Aβ1–42 phagocytosis,
cells were pre-incubated with hrANXA1 (5 μg/ml) 30 min
prior incubation with 5-FAM-labelled Aβ1–42. To further
evaluate the involvement of FPR2 on Aβ1–42 phagocytosis,
cells were pre-incubated with WRW4 (5 μM) 20 min prior
to incubation with hrANXA1. Following phagocytosis,
cells were washed three times with cold PBS and detached
from plates by using trypsin (0.20 %). Cells collected were
fixed with 2 % PFA for 10 min at room temperature. Im-
aging flow cytometry was performed on an ImageStreamx
Mark II operated by INSPIRE software (Amnis Corpor-
ation). The 5-FAM-labelled Aβ1–42 fluorescence was re-
corded using excitation with a 488-nm laser at 50-mW
intensity and emission collected with a 480–560-nm filter
in the camera 2 (CH2), while bright-field images were col-
lected in the cameras 1 (CH1) and 9 (CH9). A sample of
BV2 cells that were not incubated with 5-FAM-labelled
Aβ1–42 (control—negative phagocytosis) was collected at
the same settings, in order to gate different cell popula-
tions (negative or positive phagocytosis). Image-based gat-
ing was performed following the method reported in
detail in Additional file 2 and Additional file 3: Figure S3.
In each experiment, a template of settings used to analyse
control cells was created and was applied to all files. A
total of 10,000 events were collected for each sample, and
data were analysed using IDEAS Application 6.1 software
(Amnis Corporation).
Statistical analysis
Data shown are mean ± standard error of the mean
(SEM). Statistical analysis was performed using GraphPad
Prism 5 software. One- or two-way analysis of variance
(ANOVA) with Bonferroni’s multiple-comparison post
hoc test were used, or when appropriate, a Kruskal-Wallis
test with Dunn’s multiple-comparison post-test or an
independent two-tailed Student’s t test, with a value of
p < 0.05 being considered statistically significant.
Results
ANXA1 is increased in postmortem brains of AD patients
and in 5XFAD mice
ANXA1 expression was determined in homogenates of
human postmortem frontal cortex from AD patients and
in age-matched healthy control brains. The results ob-
tained from Western blotting analysis revealed an in-
crease of ~20 % in the expression of ANXA1 (37 kDa)
in AD brains compared with matched controls (n = 21
controls and 22 sporadic AD cases, Fig. 1a). Supporting
data obtained in human AD cases, a 50 % increase in
ANXA1 expression was also observed in brain homoge-
nates of 5XFAD mice at 12 weeks of age (n = 6/group,
Fig. 1b). However, at 26 weeks of age, when the animals
show extensive amyloid plaque deposition, there were
no significant differences in ANXA1 levels between
5XFAD mice and wild-type controls. We did not ob-
serve changes in FPRL1/FPR2 expression in either
AD patients (Additional file 4: Figure S4A) or animal
models (Additional file 4: Figure S4B).
In addition, immunostaining of ANXA1 in hippocam-
pal sections from AD patients showed neuronal (Fig. 1c)
as well as microglial (Fig. 1d) and astrocytic (Fig. 1e)
staining. Intriguingly, ANXA1 was highly expressed in
neuronal tangles (marked by arrows), indicating a poten-
tial role of ANXA1 in neuronal pathology in AD.
Treatment of neuroblastoma cells with recombinant
ANXA1 reduces the levels of soluble Aβ
Because ANXA1 is expressed by neurons (Fig. 1c), we
investigated the effect of ANXA1 on APP processing in
a neuroblastoma cell line. Consequently, N2asw cells
were incubated for 18 h with different concentrations of
hrANXA1 ranging from 0.5 to 4 μg/ml (corresponding
to 13 to 105 nM). Our data show that hrANXA1 in-
duced a concentration-dependent decrease in the levels
of Aβ in the media of these cells (Fig. 2a). Conversely,
ANXA1 knockdown using siRNA transfection resulted
in an increase in Aβ secretion (Fig. 2a).
The reduction in Aβ was not secondary to alterations
in the expression of APP or the processing of APP by α-
secretase, as no changes were detected in the expres-
sion of full-length APP in cell lysates (Fig. 2b) or in
sAPPα in the conditioned medium (Fig. 2c). To deter-
mine whether incubation with recombinant ANXA1 de-
creased Aβ by altering the amyloidogenic pathway, the
levels of β-carboxy-terminal-fragments (CTFs), as
measurement of β-secretase activity, were quantified,
showing no changes with hrANXA1 treatment (Fig. 3a).
Similar results were obtained performing an in vitro
β-secretase assay (Fig. 3e). Additionally, no effects on
the BACE1 protein and BACE1 mRNA expression
by treatment with hrANXA1 (0.5–2 μg/ml) were
confirmed in N2asw and in human neuroblastoma SK-
N-SH cells (Fig. 3b–d).
Therefore, these results suggest that ANXA1 re-
duces Aβ levels in neurons, and this effect is not
mediated by changes in the expression or enzymatic
cleavage of APP.
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hrANXA1 increases the expression and activity of
Aβ-degrading enzyme neprilysin
To understand the mechanism behind ANXA1’s effect
on reducing Aβ levels in N2a cells we investigated the
effect of ANXA1 on Aβ clearance. For this purpose, syn-
thetic Aβ1–42 peptide (0.1 μM) was added to the medium
of N2asw cells over 48 h with or without 10 nM
hrANXA1 (Fig. 4a). In cells treated with hrANXA1, the
levels of Aβ1–42 synthetic peptide were reduced at faster
rate compared with control cells (two-way ANOVA, ef-
fect of treatment F(1,14) = 11.60, p = 0.0043; effect of
time F(3,14) = 64.71, p < 0.0001) (Fig. 4a). These results
show that the stability of synthetic Aβ peptide in the
medium is affected in cells treated with hrANXA1.
We then examined whether stimulation with hrANXA1
induced an increase in enzymatic mechanisms of Aβ deg-
radation. The expression levels of Aβ-degrading enzymes,
insulin-degrading enzyme (IDE) and neprilysin were
assessed by Western blot. Interestingly, 2-μg/ml hrANXA1
treatment of N2asw cells led to a significant increase in
neprilysin expression (Fig. 4b), which paralleled with
higher neprilysin activity levels (Fig. 4c). This effect was
partially reversed by the non-selective FPR inhibitor Boc1
(5 μg/ml) (Fig. 4c), indicating that the effect might be me-
diated by the binding of ANXA1 to FPR receptors. Similar
results were obtained in human SK-N-SH cells treated with
2-μg/ml hrANXA1, showing increased neprilysin expres-
sion, which was attenuated by the selective FPR2 inhibitor
WRW4 (5 μM) (Fig. 4d). We had previously proven the ex-
pression of FPR in both types of cells (Additional file 4:
Figure S4C-D). This effect was associated with an increase
in neprilysin transcription, with quantitative RT-PCR ex-
periments showing higher neprilysin gene (MME) expres-
sion in SK-N-SH cells treated with 2 μg/ml hrANXA1
Fig. 1 ANXA1 is increased in postmortem brains of AD patients and in 5XFAD mice. a Representative blots and quantification of ANXA1
expression in the frontal cortex of neurologically healthy controls and sporadic Alzheimer’s patients and normalised to β-actin (n = 20 controls, 12
males, 8 females, range 40–97 years, mean age 73.24 ± 4 years, n = 22 AD cases, 11 males, 11 females, range 42–98 years, mean age 79.09 ± 3 years).
b Representative blots and quantification of ANXA1 expression in the cortex of 5XFAD mice and wild-type littermates and normalised to β-actin
(n = 6/group, males aged 12 and 26 weeks). c–e Representative images of human postmortem AD brain hippocampal sections stained for ANXA1.
Arrows indicate expression in neurons (c), microglia (d) and astrocytic (e) staining. Values shown in graphs represent the mean value ± SEM and are
expressed as fold change in comparison to the normalized control. Statistical analysis included Student’s independent two-tailed t test, *p < 0.05
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(Fig. 4e). The levels of IDE however were non-significantly
altered by 2–4 μg/ml hrANXA1 treatment in both mouse
N2asw (Fig. 4f) and human SK-N-SH cells (Fig. 4g).
hrANXA1 increases microglial phagocytosis of Aβ1–42
Since microglia plays a crucial role in removing Aβ1–42
and we have previously shown that ANXA1 has an im-
portant role in efferocytosis or phagocytosis/phagoapop-
tosis [12], we tested the effects of endogenous ANXA1
on microglial phagocytosis of Aβ1–42 using fluorescently
labelled Aβ1–42 or scrambled Aβ1–42 by FACS analysis.
BV2 cells incubated with 5-FAM-labelled Aβ1–42 (3 μg/
ml) for 3 h in medium that had been conditioned by
BV2 cells overnight (unchanged media) showed higher
phagocytic activity compared to 5-FAM-labelled Aβ1–42
(3 μg/ml, 3 h) added into fresh new media (Fig. 5a). This
suggests that an endogenous molecule released by the
microglia in unchanged media had a positive effect on
enhancing Aβ1–42 phagocytosis. The specificity of this
observation was shown by the lack of effect of ANXA1
on the phagocytosis of scrambled Aβ1–42. Since BV2
cells secrete ANXA1 into the supernatant [12], we next
tested whether the factor released by microglia contrib-
uting to Aβ1–42 phagocytosis was indeed ANXA1. For
this reason, 5-FAM-labelled Aβ1–42 phagocytosis was de-
termined in BV2 cells with conditioned media including
a neutralizing ANXA1 antibody (20 ng/ml) or IgG con-
trol antibody. The results in Fig. 5b show that treatment
with anti-ANXA1-antibody-resulted in a reduction in 5-
FAM-labelled Aβ1–42 phagocytosis, which was not de-
tected with anti-IgG antibody control.
To further confirm the specificity of the effect of en-
dogenous ANXA1 on Aβ1–42 phagocytosis, we tested the
effect of ANXA1 knockdown on microglial phagocytosis
of 5-FAM-labelled Aβ1–42. BV2 cells infected with shRNA
lentivirus (wild type, PKCO, and shRNA ANXA1—clone
492) were incubated (3 h) with 5-FAM-labelled Aβ1–42
(5 μg/ml), and phagocytosis was measured using an im-
aging flow cytometer (ImageStream). The efficiency of the
shRNA infection is shown in Additional file 1: Figure S1.
As illustrated in Fig. 5c, the phagocytosis of 5-FAM-
labelled Aβ1–42 was significantly reduced in ANXA1
knockdown cells in comparison to control BV2 cells and
mock-infected BV2 cells. The representative histograms of
image-based cytometry analysis of 5-FAM-labelled Aβ1–42
phagocytosis are shown in Additional file 3: Figure S3D.
Furthermore, we investigated the pharmacological ef-
fect of ANXA1 on Aβ1–42 phagocytosis, and BV2 cells
were pre-incubated with 5 μg/ml of hrANXA1 30 min
prior to incubation with 5-FAM-labelled Aβ1–42. Results
presented in Fig. 5c show clearly the ability of the
recombinant molecule to stimulate the phagocytosis
Fig. 2 Treatment of neuroblastoma cells with recombinant ANXA1 reduces the levels of soluble Aβ. a Representative Western blots and
quantification of soluble Aβ in the medium of N2asw cells treated with 0.5–4 μg/ml hrANXA1 for 18 h (n = 9–24 samples) or transfected with
control or ANXA1 siRNA (n = 15 samples). b Representative Western blots and quantification of full-length APP protein expression in N2asw cells
treated with 1–4 μg/ml hrANXA1 for 18 h (n = 3–11 samples) or transfected with control or ANXA1 siRNA (n = 15 samples) and normalised to
β-actin. c Representative Western blots and quantification of soluble APPα in the medium of N2asw cells treated with 1–4 μg/ml hrANXA1 for
18 h (n = 3–11 samples). Values shown in graphs represent the mean value ± SEM and are expressed as fold change in comparison to the normalized
control. Statistical analysis included one-way ANOVA with Bonferroni’s multiple-comparison post-test or independent two-tailed Student’s t test,
*p < 0.05, **p < 0.01, ****p < 0.0001
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of 5-FAM-labelled Aβ1–42, further supporting our hy-
pothesis that ANXA1 stimulates the uptake of Aβ1–
42 in a non-phlogistic manner.
Next, we explored the involvement of FPR2 on the
ANXA1-mediated increase on Aβ1–42 phagocytosis. BV2
cells were pre-incubated with WRW4, a specific antag-
onist of FPR2, 20 min prior to incubation with
hrANXA1. The pharmacological blockage of FPR2
clearly reversed the ANXA1-mediated effect on Aβ1–42
phagocytosis (Fig. 5c), suggesting that ANXA1 affects
microglial phagocytosis of Aβ1–42 by a mechanism
dependent on the activation of FPR2 (two-way
ANOVA, interaction F(6,41) = 23.04, p < 0.0001; effect
of cell line F(2,41) = 13.65, p < 0.0001; effect of treat-
ment F(3,41) = 95.70, p < 0.0001.
Additionally, and in order to determine if the effect of
ANXA1 on microglial phagocytosis was mediated through
changes in the expression of microglial receptors involved
in receptor-mediated endocytosis, we measured the ex-
pression of a variety of these receptors, including the re-
ceptor for advanced glycation end-products (RAGE), the
scavenger receptor macrophage receptor with collagenous
structure (MARCO) and FPR in BV2 cells. Although the
expression of these receptors seemed to be modified by
incubation with synthetic Aβ, the effects were not re-
versed or modified by ANXA1 treatment (Fig. 5d–f ).
ANXA1 reduces the Aβ-induced expression of
pro-inflammatory cytokines in microglia
It is widely accepted that exposure of microglial cells to
Aβ induces an inflammatory response, characterised by
the secretion of cytokines and other pro-inflammatory
molecules (see review [2]). Since ANXA1-mediated
phagocytosis should work in a non-phlogistic manner,
Fig. 3 Treatment of neuroblastoma cells with recombinant ANXA1 does not affect BACE1 activity or expression. a Representative Western blots
and quantification of β-CTF expression in N2asw cells treated with 2–4 μg/ml hrANXA1 for 18 h (n = 9–18 samples) or transfected with control or
ANXA1 siRNA (n = 9 samples) and normalised to full-length APP. b Representative Western blots and quantification of BACE1 protein expression
in N2asw cells treated with 2–4 μg/ml hrANXA1 for 18 h and normalised to GAPDH (n = 6–12 samples). c Representative Western blots and
quantification of BACE1 protein expression in SK-N-SH cells treated with 0.5–2 μg/ml hrANXA1 for 18 h and normalised to GAPDH (n = 15–27
samples). d Quantification of BACE1 mRNA expression by qPCR analysis in SK-N-SH cells treated with 2 μg/ml hrANXA1 for 18 h (n = 9 samples).
e Quantification of β-secretase activity in N2asw cells following treatment with 4 μg/ml hrANXA1 for 18 h (n = 5 samples). Values shown in graphs
represent the mean value ± SEM and are expressed as fold change in comparison to the normalized control
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 hrANXA1 treatment increases the expression and activity of Aβ-degrading enzyme neprilysin. a Representative Western blots and
quantification of synthetic Aβ1–42 monomers expression in the medium of N2asw cells incubated with synthetic Aβ1–42 (0.1 μM), following 0–48-h
treatment with 10-nM hrANXA1 assessed by Western blotting using 6E10 antibody (n = 3). b Representative Western blots and quantification of
neprilysin protein expression in N2asw cells treated with 4 μg/ml hrANXA1 and/or the non-selective FPR inhibitor Boc1 (5 μg/ml) for 18 h, normalised
to β-actin (n = 10–37 samples). c Quantification of neprilysin activity in N2asw cells treated with 4 μg/ml hrANXA1 and/or the non-selective FPR
inhibitor Boc1 (5 μg/ml) for 18 h (n = 2–8 samples). d Representative Western blots and quantification of neprilysin protein expression in SK-N-SK cells
treated with 2 μg/ml hrANXA1 and/or selective FPR2 inhibitor WRW4 (5 μM) for 18 h normalised to GAPDH (n= 11–21 samples). e Quantification of
MME (neprilysin) mRNA expression by qPCR analysis in SK-N-SK cells treated with 2 μg/ml hrANXA1 for 18 h (n = 5–6 samples). f Representative Western
blots and quantification of IDE protein expression in N2asw cells treated with 2–4 μg/ml hrANXA1 for 18 h and normalised to GAPDH. g Representative
Western blots and quantification of IDE protein expression in SK-N-SK cells treated with 2 μg/ml hrANXA1 and/or selective FPR2 inhibitor WRW4 (5 μM)
for 18 h, normalised to GAPDH (n = 10–18 samples). Values shown in graphs represent the mean value ± SEM and are expressed as a percentage
change in comparison to the normalized control or fold change of control. Statistical analysis included two-way ANOVA, one-way ANOVA with
Bonferroni’s multiple-comparison post-test, Kruskal-Wallis test with Dunn’s multiple-comparison post-test or unpaired Student’s two-tailed t test
as appropriate, *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 5 ANXA1 increases microglial phagocytosis of Aβ1–42. a–b Phagocytosis of 5-FAM-labelled-Aβ1–42 or 5-FAM-labelled-scrambled Aβ1–42 by BV2
microglia incubated for 3 h with 3 μg/ml of these compounds in medium that has been conditioned by BV2 cells for 18 h overnight or freshly
changed prior to Aβ incubation (n = 9), measured by FACS. b Phagocytosis of 5-FAM-labelled-Aβ1–42 (3 μg/ml) by BV2 microglia after 3-h
incubation with anti-ANXA1-antibody (20 ng/ml) or anti-IgG-antibody when medium has been conditioned by BV2 cells overnight, measured by
FACS (n = 9). c Phagocytosis of 5-FAM-labelled-Aβ1–42 (5 μg/ml) incubated for 3 h with BV2 microglia (untransfected, control shRNA or ANXA1
shRNA transfected) in the absence or presence of hrANXA1 (5 μg/ml) and/or selective FPR2 antagonist WRW4 (5 μM) (n = 3–9). d–f Quantification
of mRNA levels of receptors involved in receptor-mediated endocytosis in BV2 cells treated with 3 μM Aβ1–42 with or without 5 μg/ml hrANXA1
for 16 h. d RAGE (n = 6 samples). e MARCO (n = 6). f FPR rs1 (n = 6). Values shown in graphs represent the mean value ± SEM and are expressed as
a percentage change in comparison to the normalized control or fold change of control. Statistical analysis included Student’s independent two-tailed
t test, one-way ANOVA with Bonferroni’s multiple-comparison post-test or two-way ANOVA with Bonferroni’s multiple-comparison post-test as
appropriate. *p < 0.05, **p < 0.01, ***p < 0.001, ****/§§§§p < 0.0001
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we measured the expression of pro- and anti-inflammatory
mediators released during BV2 incubation with synthetic
Aβ1–42. The levels of IL6 (Il6) (Fig. 6a), TNFα (Tnf) (Fig. 6b)
and IL4 (Il4) (Fig. 6c) mRNAs were found increased in
BV2 cells activated by synthetic Aβ1–42, and the expression
of Il6 and Tnf was clearly reduced by incubation with re-
combinant ANXA1. Conversely, the anti-inflammatory
arginase-1 (Arg1), IL10 (Il10) and TGF-β1 (Tgfb1) were re-
duced by incubation with Aβ1–42 (Fig. 6d–f), and only
Tgfb1 levels were restored after exposure to hrANXA1
(Fig. 6f). Therefore, these results support the anti-
inflammatory role of ANXA1 in reversing the inflamma-
tory response induced by Aβ in microglia.
Discussion
During the last decade, ANXA1 has gained interest as a
potential pharmacological tool for the treatment of neu-
rodegenerative disorders, including multiple sclerosis
[14], stroke [31] and Parkinson’s disease [32]. Previously,
we reported that ANXA1 expression is increased in
microglia in close proximity to Aβ plaques using AD
postmortem brain tissue [12]. In the present study, we
demonstrate that brains of AD patients and a murine
transgenic model of amyloidosis express higher levels of
ANXA1, not only in microglia but also in astrocytes and
neurons. The increases in ANXA1 observed in AD
brains suggest that upregulation of ANXA1 could repre-
sent an adaptive response of microglia during inflamma-
tory conditions and an attempt of the system to calm
down the inflammation at early stages of the disease,
since ANXA1 effectively solves the phase of inflamma-
tion. However, this was not observed in older animals
with more severe AD pathology. This is in agreement
with evidence reported in animal models of AD demon-
strating that at early stages of the disease, glial cells may
have a neuroprotective phenotype, secreting anti-
inflammatory molecules [33, 34] and increasing Aβ
phagocytosis. However, in later stages with chronic pro-
duction of Aβ and pro-inflammatory cytokines, micro-
glia change their neuroprotective phenotype in favour of
a more pro-inflammatory activation state through the
release of cytokines and chemokines. Interestingly, we
found that the differential expression of ANXA1 in
5XFAD mice seemed to correlate with the levels of pro-
Fig. 6 ANXA1 reduces the Aβ-induced expression of pro-inflammatory mediators in microglia. Quantification of mRNA levels of inflammatory
mediators in BV2 cells treated with 3 μM Aβ1–42 with or without 5 μg/ml hrANXA1 for 16 h. a Il6 (n = 6–12 samples). b Tnf (n = 6–17). c Il4
(n = 6–9 samples). d Arg1 (n = 6–9 samples). e Il10 (n = 6–14 samples). f Tgfb1 (n = 6 samples). Values shown in graphs represent the mean value ± SEM
and are expressed as fold change in comparison to the normalized control. Statistical analysis included one-way ANOVA with Bonferroni’s
multiple-comparison post-test or Kruskal-Wallis test with Dunn’s multiple-comparison post-test, *p < 0.05, **p < 0.01
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inflammatory cytokines IL-6 and TNFα (Additional file
5: Figure S5E,F) and not with the expression of Aβ
(Additional file 5: Figure S5G,H) or FPR (Additional file
5: Figure S5A-C). Therefore, our results indicate that the
increases in ANXA1 appear to be more related to the in-
flammatory response following Aβ deposition rather
than the levels of Aβ in the brain.
Since ANXA1 was expressed in neurons from AD pa-
tients, we investigated the in vitro effects of ANXA1 on
Aβ generation and degradation using a neuronal cell
line. We found that ANXA1 seems to be involved in the
degradation of Aβ by neuronal cells by inducing the ex-
pression of neprilysin. Neprilysin (NEP), also known as
CALLA (common acute lymphocytic leukaemia (ALL)
antigen), enkephalinase, neutral endopeptidase 24.11,
membrane metalloendopeptidase (MME) and CD10
antigen [35–37], belongs to the family of M13 zinc-
metalloendopeptidases [38]. In the brain, NEP is consid-
ered a major amyloid-degrading enzyme [39] and is
mainly located on neuronal cells, especially in the stria-
tonigral pathway [40, 41]. In addition, it is involved in
other important neuronal functions, cleaving substrates
such as substance P, met- and leu-enkephalin, FMLP, the
bombesin-like peptides, atrial natriuretic factor, endothe-
lin and oxytocin [39]. Its regulation and reactivation
have been extensively studied in the last decade. Factors
that affect NEP expression often differ between neural
and non-neural tissues as there are several NEP mRNAs
which show cell- and tissue-specific expression [42]. In
neurons, the neuropeptide somatostatin [43] and vitamin
D are able to upregulate NEP activity [44]. Recently, it
was shown that the APP intracellular domain (AICD)
fragment derived from the γ-secretase cleavage of APP
was also able to regulate the transcription of NEP [45].
Expression of the NEP gene is controlled through two
distinct promoters [46] whose role differs between cell
types, although both promoters show similar character-
istics and activity. Interestingly, our study suggests that
incubation of neuroblastoma cells with recombinant
ANXA1 lead to an increase in NEP expression and this
effect was reversed by FPR2 inhibitors. These results
suggest that FPRL1/FPR2 activation by ANXA1 can
regulate NEP expression, although this hypothesis needs
to be further confirmed by experiments in FPRL1/FPR2
knockout cells. Similar to somatostatin receptors, FPR
receptors are G protein-coupled receptors, which upon
activation, trigger several agonist-dependent signal trans-
duction pathways [47]. We do not rule out that ANXA1
could affect Aβ degradation by alternative mechanisms
that do not involve FPRL1/FPR2 activation. ANXA1 can
bind phospholipids in cellular membranes in a dynamic
and reversible fashion in a Ca2+-dependent manner. This
interaction can affect Ca2+ signalling and allows ANXA1
to contribute to the organization of membrane domains
or signalling platforms and the formation of complex
protein networks [48].
Additionally, we demonstrate that recombinant
ANXA1 increases Aβ uptake in microglial BV2 cells and
that its knockdown reduces Aβ phagocytosis. This result
is in agreement with the data from Yona et al. (2006),
who reported that lack of ANXA1 leads to reduced
phagocytosis in ANXA1 knockout cells in the peripheral
nervous system [49]. The presence of ANXA1 on the
phagosomal membrane appears to be functionally im-
portant in macrophages and neutrophils. It seems, how-
ever, that the effects are more specific for Aβ42 than for
any particle, since the phagocytosis of the scrambled Aβ
peptide was less affected by ANXA1. It is well accepted
that Aβ1–42 binds to FPRL1/FPR2 and is rapidly interna-
lised into the cytoplasmic compartment of phagocytic
cells [50]. Branderburg et al. (2008) have shown that the
Aβ/FPRL1 complex co-localises with clathrin-coated
endocytotic vesicles, and the activation of phospholipase
D (PLD) seems to play an important role in the internal-
ization of the Aβ/FPRL1 complex [51, 52]. In addition,
FPRL1/FPR2 can interact with scavenger receptors in
glial cells and this association has been reported to be
important for Aβ1–42-mediated signal transduction [53].
One potential mechanism by which ANXA1 could affect
Aβ endocytosis includes the interaction of ANXA1 with
the actin cytoskeleton [54]. ANXA1 binds to and bun-
dles F-actin in vitro and co-localises with F-actin in dif-
ferent cell lines [14, 55]. In vitro studies have shown that
ANXA1 facilitates the interaction between F-actin and
phagosomes on macrophages, whereas the knockdown
of ANXA1 expression resulted in impaired phagocytosis
[54]. Our results suggest that the interaction between
ANXA1 and FPRL1/FPR2 is functionally important to
the formation of the phagosomal membrane on micro-
glia and Aβ phagocytosis.
In addition to the effect of ANXA1 on Aβ phagocyt-
osis, we have shown that ANXA1 was able to reverse
the pro-inflammatory effects of Aβ1–42 on microglia by
regulating the genetic expression of Il6, Tnf and Tgfb1.
These results are in agreement with a previous study
from our group showing that ANXA1 was able to re-
verse the LPS-induced activation of microglia [12].
Moreover, macrophages from mice lacking ANXA1
showed higher levels of TNFα and IL-6 in response to
LPS [56]. These results confirm that ANXA1 regulates
microglial activation in response to inflammatory
stimuli.
Conclusions
Our data support a potential role of ANXAl in AD by
reducing Aβ levels and decreasing neuroinflammation,
suggesting a novel view that ANXAl may play a protect-
ive role in AD progression. We have shown in this study
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that ANXA1 affects the degradation and clearance of Aβ
and propose ANXA1 as a promising therapeutic tool in
AD. However, in spite of the protective role of ANXA1
in AD, more studies should be conducted in order to
clarify possible regulatory mechanisms in this resolution
pathway, which may affect its functionality in different
stages of the disease.
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Additional file 1: Figure S1. Efficiency of ANXA1 shRNA infection in
BV2 cells. Representative Western blot image showing protein expression
of ANXA1 in BV2 cells infected with control shRNA, and ANXA1
shRNA—clones 492A, 492B, 495A and 495B. Band intensities were
determined using ImageJ and normalised to tubulin. (PDF 99 kb)
Additional file 2: Supplementary methods. (DOC 22 kb)
Additional file 3: Figure S3. ImageStream quantification of 5-FAM-
labelled Aβ1–42 phagocytosis by BV2 cells. Histogram showing gating
of BV2 cells. B. Scatterplot showing gating of focused BV2 cells. C. Histogram
and representative images of negative and positive 5-FAM-labelled Aβ1–42
phagocytosis by BV2 cells. D. Representative histograms of 5-FAM-labelled
Aβ1–42 phagocytosis by BV2 cells (WT, control shRNA and shRNA ANXA1)
incubated for 3 h with 5-FAM-labelled Aβ1–42 (5 μg/ml) added to
BV2-conditioned medium. (PDF 865 kb)
Additional file 4: Figure S4. Expression of FPRL1/FPR2 in human and
mouse samples and in N2asw, SK-N-SH and BV2 cell lines. A. Representative
Western blots and quantification of FPRL1/FPR2 protein expression in the
frontal cortex of neurologically healthy controls and sporadic Alzheimer’s
patients and normalised to β-actin (n = 5 controls, 3 males, 2 females, range
81–97 years, mean age 86.8 ± 3 years, n = 7 AD cases, 3 males, 4 females,
range 83–98 years, mean age 91.3 ± 2 years). B. Representative blots and
quantification of FPRL1/FPR2 expression in the cortex of 5XFAD mice and
wild-type littermates and normalised to β-actin (n = 6/group, males aged 12
and 26 weeks). C-E. Histograms showing mean intensity fluorescence (FL1)
of FPRL1/FPR2 expression (red line) on (C) N2asw, (D) SK-N-SH and (E) BV2
cells analysed by FACS. Black lines shows FL1 of N2asw, SK-N-SH and BV2
cells incubated with goat anti-rabbit FITC-conjugated IgG. Values shown in
graphs represent the mean value ± SEM and are expressed as fold change
in comparison to the normalized control. (PDF 1076 kb)
Additional file 5: Figure S5. Correlation of ANXA1 expression with FPR,
cytokines and Aβ. A. Scatterplot showing relationship between FPRL1/
FPR2 and ANXA1 protein expression assessed by Western blotting in the
frontal cortex of neurologically healthy controls and sporadic Alzheimer’s
patients (n = 5 controls, 3 males, 2 females, range 81–97 years, mean age
86.8 ± 3 years; n = 7 AD cases, 3 males, 4 females, range 83–98 years,
mean age 91.3 ± 2 years). B. Scatterplot showing relationship between
FPRL1/FPR2 and ANXA1 protein expression assessed by Western blotting
in the motor cortex of 5XFAD mice and wild-type littermates and (n = 6/
group, males aged 12 and 26 weeks). C. Scatterplot showing relationship
between FPR rs1 and ANXA1 mRNA expression assessed in the frontal
cortex of 5XFAD mice and wild-type littermates by qPCR (n = 19, males
aged 12 and 26 weeks). D. Scatterplot showing relationship between
ANXA1 protein expression assessed by Western blotting and TNFα
expression measured by ELISA in in the frontal cortex of neurologically
healthy controls and sporadic Alzheimer’s patients (n = 8 controls, 5
males, 3 females, range 40–82 years, mean age 67.1 ± 6 years; n = 10 AD
cases, 7 males, 3 females, range 42–98 years, mean age 72.5 ± 6 years). E.
Scatterplot showing relationship between Tnf and ANXA1 mRNA expression
assessed in the frontal cortex of 5XFAD mice and wild-type littermates by
qPCR (n = 18, males aged 12 and 26 weeks). ***p < 0.001, r2 = 0.5779. F.
Scatterplot showing relationship between Il6 and ANXA1 mRNA expression
assessed in the frontal cortex of 5XFAD mice and wild-type littermates by
qPCR (n= 19, males aged 12 weeks and 26 weeks). ****p< 0.0001, r2 = 0.6352.
G. Scatterplot showing relationship between ANXA1 protein expression
assessed by Western blotting and Aβ1–40 expression measured by ELISA in
the frontal cortex of neurologically healthy controls and sporadic Alzheimer’s
patients (n= 10 controls, 6 males, 4 females, range 40–97 years, mean age
71.5 ± 6 years; n= 12 AD cases, 8 males, 4 females, range 42–98 years, mean
age 74.4 ± 5 years). H. Scatterplot showing relationship between Aβ and
ANXA1 protein expression assessed by Western blotting in the cortex of
5XFAD mice (n= 11, males aged 12 and 26 weeks). (PDF 111 kb)
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